Suppression of diabetic retinopathy with GLUT1 siRNA

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  You, Zhi Peng ^a   Zhang, Yu Lan ^a   Shi, Ke ^a   Shi, Lu ^a   Zhang, Yue Zhi ^a   Zhou, Yue ^a   Wang, Chang yun ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ERG PROTEIN, MOUSE; GLUCOSE; GLUCOSE TRANSPORTER 1; INTERCELLULAR ADHESION MOLECULE 1; ONCOPROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ERG; TUMOR NECROSIS FACTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; EXPERIMENTAL DIABETES MELLITUS; GENETICS; INTRAVITREAL DRUG ADMINISTRATION; MALE; METABOLISM; MOUSE; RETINA; TREATMENT OUTCOME;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; INTERCELLULAR ADHESION MOLECULE-1; INTRAVITREAL INJECTIONS; MALE; MICE; ONCOGENE PROTEINS; RETINA; RNA, SMALL INTERFERING; TRANSCRIPTIONAL REGULATOR ERG; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85051262349     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-07942-x     Document Type: Article

References (29)

1. International Diabetes Federation. IDF Diabetes Atlas 7th edn (2015)
2. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group et al. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N. Engl. J. Med. 342, 381–389 (2000)
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837–853 (1998)
4. Wong, T. Y., Simó, R. & Mitchell, P. Fenofibrate - a potential systemic treatment for diabetic retinopathy? Am. J. Ophthalmol. 154, 6–12 (2012)
5. Chen, M., Curtis, T. M. & Stitt, A. W. Advanced glycation end products and diabetic retinopathy. Curr. Med. Chem. 20, 3234–3240 (2013)
6. Sjølie, A. K., Dodson, P. & Hobbs, F. R. Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review. Int. J. Clin. Pract. 65, 148–153 (2011)
7. Kumagai, A. K. Glucose transport in brain and retina: implications in the management and complications of diabetes. Diabetes Metab. Res. Rev. 15, 261–273 (1999)
8. Lu, L. et al. Suppression of GLUT1; a new strategy to prevent diabetic complications. J Cell Physiol. 228, 251–257 (2013)
9. Ryan, S. J. Retina 4th edn (Elsevier, 2010)
10. Agrawal, N. K. & Kant, S. Targeting inflammation in diabetes: newer therapeutic options. World J. Diabetes 5, 697–710 (2014)
11. Li, C. et al. Oxidative stress-related mechanisms and antioxidant therapy in diabetic retinopathy. Oxid. Med. Cell. Longev. 2017, 9702820 (2017)
12. Thorens, B. & Mueckler, M. Glucose transporters in the 21st century. Am. J. Physiol. Endocrinol. Metab. 298, E141–E145 (2010)
13. Kumagai, A. K., Vinores, S. A. & Pardridge, W. M. Pathological upregulation of inner blood-retinal barrier Glut1 glucose transporter expression in diabetes mellitus. Brain Res 706, 313–317 (1996)
14. Fernandes, R., Suzuki, K. & Kumagai, A. K. Inner blood-retinal barrier GLUT1 in long-term diabetic rats: an immunogold electron microscopic study. Invest Ophthalmol Vis Sci 44, 3150–3154 (2003)
15. Fernandes, R. et al. Downregulation of retinal GLUT1 in diabetes by ubiquitinylation. Mol Vis 10, 618–628 (2004)
16. Badr, G. A., Tang, J., Ismail-Beigi, F. & Kern, T. S. Diabetes downregulates GLUT1 expression in the retina and its microvessels but not in the cerebral cortex or its microvessels. Diabetes 49, 1016–1021 (2000)
17. Wang, Y., Li, S. J. & Liao, J. X. Experiment study on screening of effectual siRNA-mediated GLUT1. J. Oral Maxil. Surg. 22, 312–317 (2012)
18. Sokolovska, J. et al. Correction of glycaemia and GLUT1 level by mildronate in rat streptozotocin diabetes mellitus model. Cell Biochem. Funct. 29, 55–63 (2011)
19. Zhang, J. Z., Gao, L., Widness, M., Xi, X. & Kern, T. S. Captopril inhibits glucose accumulation in retinal cells in diabetes. Invest. Ophthalmol. Vis. Sci. 44, 4001–4005 (2003)
20. Énzsöly, A. et al. Pathologic alterations of the outer retina in streptozotocin-induced diabetes. Invest. Ophthalmol. Vis. Sci. 55, 3686–3699 (2014)
21. Lung, J. C., Swann, P. G. & Chan, H. H. Early local functional changes in the human diabetic retina: a global flash multifocal electroretinogram study. Graefes Arch. Clin. Exp. Ophthalmol. 250, 1745–1754 (2012)
22. Verma, A. et al. Is neuronal dysfunction an early sign of diabetic retinopathy? Microperimetry and spectral domain optical coherence tomography (SD-OCT) study in individuals with diabetes, but no diabetic retinopathy. Eye (Lond) 23, 1824–1830 (2009)
23. Gaillard, F., Kuny, S. & Sauvé, Y. Topographic arrangement of S-cone photoreceptors in the retina of the diurnal Nile grass rat (Arvicanthisniloticus). Invest. Ophthalmol. Vis. Sci. 50, 5426–5434 (2009)
24. Miyamoto, K. et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc. Natl Acad. Sci. USA 96, 10836–10841 (1999)
25. Joussen, A. M. et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 18, 1450–1452 (2004)
26. Tsuchihashi, S. et al. Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia/reperfusion injury. Am. J. Pathol. 168, 695–705 (2006)
27. Tian, P. et al. Leukocytes from diabetic patients kill retinal endothelial cells: effects of berberine. Mol. Vis. 19, 2092–2105 (2013)
28. Zhang, H. T. et al. Silybin reduces obliterated retinal capillaries in experimental diabetic retinopathy in rats. Eur. J. Pharmacol. 740, 233–239 (2014)
29. Zhang, Q. & Steinle, J. J. IGFBP-3 inhibits TNF-alpha production and TNFR-2 signaling to protect against retinal endothelial cell apoptosis. Microvasc. Res. 95, 76–81 (2014)